NATCO Pharma Ltd updates on complaint by Fresenius

NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) would like to update that Fresenius Kabi USA, LLC and Fresenius Kabi Deutschland GmbH (together, "Fresenius") have filed a complaint against Natco Pharma USA LLC f/k/a Dash Pharmaceuticals LLC in the District Court of Delaware relating to the marketing of Dash Pharmaceuticals Diazepam Injection prefilled syringe in the United States. Fresenius has not yet effectuated service of the complaint which is required to commence the lawsuit.

Natco Pharma intends to defend the matter accordingly.

Dash Pharmaceuticals LLC had been acquired by Natco Pharma, Inc. and Dash Pharmaceuticals LLC had changed its name to Natco Pharma USA LLC.

Shares of Natco Pharma Limited was last trading in BSE at Rs. 998.45 as compared to the previous close of Rs. 994.50. The total number of shares traded during the day was 15796 in over 1092 trades.

The stock hit an intraday high of Rs. 1004.80 and intraday low of 980.45. The net turnover during the day was Rs. 15759435.00.

Source : Equity Bulls

Keywords

NatcoPharma INE987B01026 Fresenius Complaint